Skip to content
Open access

REG1A as an oral biomarker for elevated blood levels of HbA1c: a machine learning approach in The Maastricht Study in a case control design

Oct 2026 · Clinical Proteomics · 0 citations

TL;DR

Reg1A, a protein linked to pancreatic β-cell regeneration, emerged as an oral biomarker for elevated HbA1c levels, suggesting that oral rinse proteomics may offer a simple, non-invasive tool for screening and monitoring elevated HbA1c levels, with potential applicability to point-of-care testing and large epidemiological studies.

Abstract

Oral fluids may provide an alternative to traditional invasive sampling methods for screening and monitoring chronic conditions, such as Type 2 diabetes mellitus (T2DM), which is commonly assessed using blood HbA1c levels. We aimed to identify putative proteomic signatures in oral rinse samples to differentiate individuals with low versus high HbA1c levels using a machine learning (ML) approach. Participants were selected from an existing population cohort (The Maastricht Study), and oral rinse samples were derived from the associated Biobank. A two-threshold ML approach used the population median threshold (37 mmol/mol), followed by the clinical cutoff for elevated HbA1c (48 mmol/mol), the diagnostic threshold for diabetes, to stratify participants into two HbA1c-based groups. Proteomic analysis of the oral rinse samples was performed using the Proximity Extension Assay (Olink ® ) targeting 92 cardiometabolic proteins. The ML approach employed repeated nested cross-validation with Boruta feature selection and evaluated Logistic Regression, Random Forest, and XGBoost. SHapley Additive exPlanations (SHAP) were used to quantify feature importance and interpret the contribution and directionality of individual proteins in the model predictions. Post hoc analyses evaluated the levels of identified proteins across HbA1c and T2DM categories and assessed potential confounding factors, including periodontitis, an oral inflammatory disease. Among the 176 participants, no discriminatory proteins were identified at the population median threshold. Using the clinical cutoff, Logistic Regression achieved the highest performance (ROC AUC: 0.78 ± 0.09; 95% CI: [0.74, 0.82]). REG1A (Regenerating Islet-Derived Protein 1 Alpha), also known as Pancreatic Stone Protein, emerged as the sole oral biomarker for elevated blood HbA1c. In the post hoc multivariable analysis, after adjusting for potential confounders, REG1A remained significantly associated with elevated HbA1c, and REG1A levels showed significant positive trends across the clinically relevant HbA1c and T2DM categories (normal, prediabetes, and diabetes). REG1A, a protein linked to pancreatic β-cell regeneration, emerged as an oral biomarker for elevated HbA1c levels. This finding suggests that oral rinse proteomics may offer a simple, non-invasive tool for screening and monitoring elevated HbA1c levels, with potential applicability to point-of-care testing and large epidemiological studies. However, validation in larger cohorts is warranted.

Read PDF

Similar papers

Open access Oct 2026

Identification of CLOCK and MARK2 as Candidate Blood-Based Biomarkers in Type 2 Diabetes: An Integrated Bulk and Single-Cell Transcriptomic Study

Any relationship between these genes and the neurological manifestations of T2DM remains speculative and hypothesis-generating, and requires prospective validation in cohorts with matched neurocognitive data.

Li-Li Yang, Jia-Hao Tang, Dong-Qing Zhang et al. · 0 citations
Open access Sep 2026

Proteomic machine-learning signatures associated with carotid plaque: A population-based hypothesis-generating study

Carotid plaque (CP) is a surrogate marker of cardiovascular disease, and high-risk morphology significantly increases the risk of stroke. The aim of this study was to develop advanced machine learning (ML) models to predict the presence of CP in the general population. The study involved 693 participants from the Polis...

A. Szpakowicz, W. Lesiński, J. Tuchliński et al. · 0 citations
Open access Sep 2026

A Molecular Diagnostic Approach for Hypertension Through Establishment of a Metabolite Risk Score Using a Multi-Metabolite Panel Identified via UHPLC-MS/MS

Hypertension (HTN) is often asymptomatic and difficult to detect using blood pressure (BP) measurements unless BP is substantially elevated. Given its association with metabolic alterations and complications, this study aimed to establish a metabolite risk score (MRS) as a molecular tool to complement BP-based diagnosi...

Youngmin Han, H. Yoo · 0 citations
Open access Sep 2026

Prediction of Type 2 Diabetes using genomics and proteomics: the HUNT Study (ProtRS for T2D)

The associated proteins and biological pathways identified represent insights into the underlying molecular mechanism of T2D and may serve as potential biomarkers for risk prediction and prevention for T2D.

Fikria Karinanur, B. Åsvold, G. Giskeødegård et al. · 0 citations
Review Open access Sep 2026

Development and validation of a model using routine clinical features to improve diabetes diagnosis

Abstract Context Hemoglobin A1c (A1c) and fasting plasma glucose (FPG) miss diabetes diagnosis in many individuals, but the alternative, oral glucose tolerance testing (OGTT), is difficult to obtain. Objective This work aimed to develop and validate a model to identify diabetes missed by A1c and FPG but detected by OGT...

A. Hutchison, Simar Narula, B. Faubert et al. · 0 citations
Open access Sep 2026

Machine learning-based discovery and clinical validation of STX12 and INPP5D as plasma biomarkers for Parkinson’s disease

Despite significant scientific progress in recent years, a notable gap remains in the availability of reliable non-invasive biomarkers for the early diagnosis of Parkinson’s disease (PD). This study aimed to identify and validate novel plasma biomarkers for PD using integrated bioinformatics and machine learning. Trans...

Cui-Yu Yang, Rong Huang, Si-Jun Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.